Birt-Hogg-Dubé综合征肾肿瘤:组织病理、批量与单细胞转录组整合分析
该研究评估20例BHD患者共84个肾肿瘤的胚系FLCN变异与结局,并整合组织病理、测序及批量/单细胞转录组分析。发现多数为惰性FLCN突变肿瘤,其表达谱不同于嗜酸细胞瘤和嫌色细胞癌,含L1CAM-/FOXI1+与L1CAM+/FOXI1-细胞群且GPNMB过表达。含L1CAM、SOX9和GPNMB的免疫组化 panel 可可靠筛查常规FMT,并建议胚系检测纳入启动子缺失事件。
要点
- BHD患者多数肾肿瘤为惰性FLCN突变肿瘤,非传统类型可能具侵袭性。
- FMT表达谱独特,含GPNMB过表达的六群细胞。
- L1CAM、SOX9、GPNMB免疫组化可筛查常规FMT。
核心结论
- 当前BHD临床胚系检测策略存在缺口,应纳入启动子缺失事件。
- 多模态分子谱可通过免疫组化生物标志物转化至常规临床,改善BHD诊断并区分惰性常规FMT与可能侵袭的非传统肿瘤。
研究设计与样本
- 评估20例BHD患者共84个肾肿瘤的胚系FLCN变异与结局。
- 对肾肿瘤进行组织病理学分析,并采用下一代测序、批量/单细胞转录组分析和免疫组化联合分析。
- 在234个无关家族中鉴定出90个独特胚系FLCN变异。
主要发现
- 234个无关家族中90个独特胚系FLCN变异包括罕见缺失事件(14/234,6%),含启动子区域缺失。
- 17/19(90%)患者符合美国国家综合癌症网络指南的胚系检测标准。
- 几乎所有病例为惰性FMT(n=81),3例非传统肾细胞癌患者中2例出现转移。
- FMT基因表达谱不同于嗜酸细胞瘤和嫌色细胞癌,以四个L1CAM-/FOXI1+和两个L1CAM+/FOXI1-细胞群为特征,均显示GPNMB过表达。
- 包含L1CAM、SOX9和GPNMB的免疫组化 panel 可作为常规FMT的可靠筛查。
关键数值与推荐
- 胚系FLCN变异中缺失事件占14/234(6%)。
- 符合NCCN胚系检测标准者17/19(90%)。
- 惰性FMT为81例;非传统肾细胞癌3例中2例转移。
- 免疫组化 panel 包含L1CAM、SOX9和GPNMB。
临床怎么用
- 对BHD患者进行胚系检测时应涵盖FLCN启动子缺失事件。
- 采用含L1CAM、SOX9和GPNMB的免疫组化 panel 筛查常规FMT。
- 通过免疫组化生物标志物区分惰性常规FMT与可能临床侵袭的非传统肿瘤。
局限性
- 缺乏外部转录组数据集以避免批次效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: It is unclear whether historically diagnosed "hybrid tumors" in patients with Birt-Hogg-Dubé syndrome (BHD) represent unique tumors or a hybrid between oncocytoma and chromophobe renal cell carcinoma (Ch-RCC), and existing diagnostic criteria are ambiguous. We aimed to understand the spectrum of folliculin gene (FLCN) alterations, outcomes for BHD patients with kidney tumors, and the biology of FLCN-mutated tumors (FMTs) to refine diagnostic algorithms. METHODS: Germline testing for FLCN alterations and outcomes for 20 BHD patients with 84 kidney tumors were evaluated. Renal tumors were profiled for histopathology and analyzed using a combination of next-generation sequencing, bulk/single-cell transcriptomic analysis, and immunohistochemistry (IHC). KEY FINDINGS AND LIMITATIONS: Ninety unique germline FLCN variants in 234 unrelated families included rare deletion events (14/234, 6%), including those of the promoter region. Most patients (17/19, 90%) met the National Comprehensive Cancer Network criteria for germline testing. Almost all cases represented indolent FMTs (n = 81), with metastases seen in two (of three) nonconventional renal cell carcinoma patients. FMTs showed a gene expression profile distinct from both oncocytoma and Ch-RCC characterized by four distinct L1CAM-/FOXI1+ and two L1CAM+/FOXI1- cell populations that showed GPNMB overexpression. IHC panels that include L1CAM, SOX9, and GPNMB can be a reliable screen for conventional FMTs. Limitations include the absence of external transcriptomic datasets to avoid batch effects. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results highlight the gaps in current clinical germline testing strategies for BHD, which should include promoter deletion events. Multimodal molecular profiling results can be translated into routine clinical practice using IHC biomarkers to improve the diagnosis of BHD and to separate indolent "conventional" FMTs from "nonconventional tumors," which may be clinically aggressive.
引用
- Gupta S, Dasari S, Warren RR, et al. Renal Neoplasia in Birt-Hogg-Dubé Syndrome: Integrated Histopathologic, Bulk, and Single-cell Transcriptomic Analysis. Eur Urol. 2025. PMID: 40253282. doi:10.1016/j.eururo.2025.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。